Admission diagnoses of patients later diagnosed with autoimmune encephalitis.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 24 08 2018
accepted: 25 10 2018
revised: 23 10 2018
pubmed: 14 11 2018
medline: 8 5 2019
entrez: 14 11 2018
Statut: ppublish

Résumé

Since the detection of autoantibodies against neuronal surface antigens, autoimmune encephalitis (AE) has been more frequently diagnosed, especially in patients with symptoms typical of limbic encephalitis, such as seizures, short-term memory deficits, or psychosis. However, the clinical spectrum of AE may be much wider, making correct clinical diagnosis difficult. We retrospectively analysed symptoms and admission diagnoses at first clinical presentation in 50 AE patients. We included patients with a clinical diagnosis of AE for whom a FDG-PET imaging was available. Final diagnoses were re-evaluated by a blinded investigator according to the most recent consensus suggestions published in 2016 for AE diagnostic criteria. We additionally describe two patients with Morvan syndrome who showed CASPR2 antibodies. In 40 patients (80.0%), the clinical presentation at first admission was typical for AE. Ten patients (20.0%) initially suffered from atypical symptoms; among these patients, isolated headache and cerebellar dysfunction were most frequent (three patients each). However, an initial diagnosis of suspected encephalitis was only reached in 16 patients (32.0%), nine (18.0) of which were suspected to have infectious encephalitis, and seven (14.0%) patients were suspected to have AE. In 34 patients (68.0%), a diagnosis other than encephalitis was considered, (e.g., epilepsy, psychiatric diseases, transient ischemic attack, dementia, meningitis, and cerebellitis). These data show the broad spectrum of initial symptoms of AE; the correct initial diagnosis of AE is often missed or delayed. Hence, clinicians in neurological and psychiatric hospitals should consider AE in the differential diagnosis of cases with atypical clinical presentations.

Sections du résumé

BACKGROUND BACKGROUND
Since the detection of autoantibodies against neuronal surface antigens, autoimmune encephalitis (AE) has been more frequently diagnosed, especially in patients with symptoms typical of limbic encephalitis, such as seizures, short-term memory deficits, or psychosis. However, the clinical spectrum of AE may be much wider, making correct clinical diagnosis difficult.
METHODS METHODS
We retrospectively analysed symptoms and admission diagnoses at first clinical presentation in 50 AE patients. We included patients with a clinical diagnosis of AE for whom a FDG-PET imaging was available. Final diagnoses were re-evaluated by a blinded investigator according to the most recent consensus suggestions published in 2016 for AE diagnostic criteria. We additionally describe two patients with Morvan syndrome who showed CASPR2 antibodies.
RESULTS RESULTS
In 40 patients (80.0%), the clinical presentation at first admission was typical for AE. Ten patients (20.0%) initially suffered from atypical symptoms; among these patients, isolated headache and cerebellar dysfunction were most frequent (three patients each). However, an initial diagnosis of suspected encephalitis was only reached in 16 patients (32.0%), nine (18.0) of which were suspected to have infectious encephalitis, and seven (14.0%) patients were suspected to have AE. In 34 patients (68.0%), a diagnosis other than encephalitis was considered, (e.g., epilepsy, psychiatric diseases, transient ischemic attack, dementia, meningitis, and cerebellitis).
CONCLUSIONS CONCLUSIONS
These data show the broad spectrum of initial symptoms of AE; the correct initial diagnosis of AE is often missed or delayed. Hence, clinicians in neurological and psychiatric hospitals should consider AE in the differential diagnosis of cases with atypical clinical presentations.

Identifiants

pubmed: 30421340
doi: 10.1007/s00415-018-9105-3
pii: 10.1007/s00415-018-9105-3
doi:

Substances chimiques

Antibodies 0
Biomarkers 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

124-132

Références

Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Exp Ther Med. 2015 Oct;10(4):1283-1292
pubmed: 26622479
Neurology. 2016 May 3;86(18):1692-9
pubmed: 27037230
Neurology. 2012 Jul 10;79(2):195-6
pubmed: 22744657
Dev Med Child Neurol. 2014 Aug;56(8):794-6
pubmed: 24641688
Front Psychiatry. 2017 Feb 16;8:25
pubmed: 28261116
Neurology. 2011 Jul 12;77(2):179-89
pubmed: 21747075
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Ann Indian Acad Neurol. 2013 Oct;16(4):577-84
pubmed: 24339583
J Neuroimmunol. 2013 Mar 15;256(1-2):94-6
pubmed: 23332614
J Neurol Neurosurg Psychiatry. 2012 Jun;83(6):638-45
pubmed: 22448032
Neurology. 2012 Sep 11;79(11):1136-44
pubmed: 22895588
Lancet Neurol. 2011 Aug;10(8):759-72
pubmed: 21777830
Curr Neurol Neurosci Rep. 2013 May;13(5):348
pubmed: 23526548
Neurology. 2016 Dec 6;87(23):2471-2482
pubmed: 27920282
Headache. 2016 Jun;56(6):995-1003
pubmed: 27241874
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Ann Neurol. 2014 Mar;75(3):411-28
pubmed: 24700511
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Neurol Sci. 2014 Jan;35(1):125-6
pubmed: 23892978

Auteurs

Annette Baumgartner (A)

Department of Neurology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. annette.baumgartner@uniklinik-freiburg.de.
Department of Psychiatry and Psychotherapy, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. annette.baumgartner@uniklinik-freiburg.de.

Sebastian Rauer (S)

Department of Neurology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Tilman Hottenrott (T)

Department of Neurology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Frank Leypoldt (F)

Institute of Laboratory Medicine and Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany.

Friederike Ufer (F)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Harald Hegen (H)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Harald Prüss (H)

Department of Neurology, Charité University Medicine Berlin and German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.

Jan Lewerenz (J)

Department of Neurology, Ulm University, Ulm, Germany.

Florian Deisenhammer (F)

Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.

Oliver Stich (O)

Medical Care Center, Neurology, Konstanz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH